Latest Breaking News On - Academy professor seppo yl - Page 1 : comparemela.com
Finnish coronavirus vaccine developer Rokote Laboratories Finland secures significant funding
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
University of Helsinki: Finnish coronavirus vaccine developer Rokote Laboratories Finland secures significant funding
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.
Finnish company receives funding to develop nasal spray Covid vaccine
yle.fi - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yle.fi Daily Mail and Mail on Sunday newspapers.
E-Mail
Credit: UEF/ Raija Törrönen
Researchers at the University of Eastern Finland have discovered previously unknown non-coding RNAs (ncRNAs) involved in regulating the gene expression of vascular endothelial growth factors (VEGF), the master regulators of angiogenesis. The study, conducted by the research groups of Associate Professor Minna Kaikkonen-Määttä and Academy Professor Seppo Ylä-Herttuala, provides a better understanding of the complex interplay of ncRNAs with gene regulation, which might open up novel therapeutic approaches in the future. The results were published in the
Molecular and Cellular Biology Journal.
Over the past years, the development of next generation sequencing techniques has revealed that around 97% of the human transcriptome is transcribed as non-coding RNAs, and although the role of the vast majority remains uncharacterized, many functions such as gene regulation have been proven.
Credit: University of Eastern Finland
Recently-formed Rokote Laboratories Finland is developing an intranasal vaccine against COVID-19 utilising specialised gene transfer technology. The company, which has emerged from University of Eastern Finland (UEF) and University of Helsinki (UHEL), is currently seeking investment to support the further development and marketisation of the vaccine, with human trials hoped to take place within the next few months.
WHY IT MATTERS
The gene transfer technology foundational to the vaccine is developed at UEF by Rokote’s own Academy Professor Seppo Ylä-Herttuala. A cloned DNA strand inside a safe adenovirus carrier incites the nasopharyngeal cells to make the SARS-CoV-2 virus protein, the virus that causes COVID-19. The vaccine does not carry any of the actual virus but rather triggers an immune response in the body.